New-type benzazepine fused ring derivative

A compound of formula (I), an optical isomer thereof, or a pharmaceutically acceptable salt thereof,

• wherein
• ring A is selected from 4- to 6-membered heterocyclyl and C3-6 cycloalkyl, and the 4- to 6-membered heterocyclyl or C3-6 cycloalkyl is optionally substituted by 1, 2, or 3 RA;
• ring B is selected from phenyl and 5- to 6-membered heteroaryl, and the phenyl or 5- to 6-membered heteroaryl is optionally substituted by 1, 2, or 3 R3;
• ring C is selected from phenyl and 5- to 6-membered heteroaryl, and the phenyl or 5- to 6-membered heteroaryl is optionally substituted by 1, 2, or 3 R4;
• T1, T2 are each independently selected from N and C(RT);
• R1, R2, R3, RA, RT are each independently selected from H, F, Cl, Br, I, CN, OH, NH2, C1-6 alkyl, and C1-6 heteroalkyl, and the C1-6 alkyl or C1-6 heteroalkyl is optionally substituted by 1, 2, or 3 R;
• each R4 is independently selected from H, F, Cl, Br, I, CN, OH, NH2, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 cycloalkyl, phenyl, and 5- to 6-membered heteroaryl, and the C1-6 alkyl, C1-6 alkoxy, C1-6 alkylamino, C3-6 cycloalkyl, phenyl, or 5- to 6-membered heteroaryl is optionally substituted by 1, 2, or 3 R4a;
• R, R4a are each independently selected from H, F, Cl, Br, I, CN, OH, NH2, C1-6 alkyl, C1-6 alkoxy, and C1-6 alkylamino, and the C1-6 alkyl, C1-6 alkoxy, and C1-6 alkylamino are optionally substituted by 1, 2, or 3 R′;
• R′ is selected from H, F, Cl, Br, I, CN, OH, NH2, and C1-6 alkyl;
• m1, m2 are each independently selected from 0, 1, or 2;
• and when ring A is selected from 4- to 6-membered heterocyclyl, the compound of formula (I) is not selected from
• the 4- to 6-membered heterocyclyl, C1-6 heteroalkyl, or 5- to 6-membered heteroaryl comprises 1, 2, 3, or 4 heteroatoms or heteroatom groups independently selected from —O—, —NH—, —S—, —C(═O)—, —C(═O)O—, —S(═O)—, —S(═O)2—, and N.